Daily Archives: March 26, 2019

Sundance Energy Australia Limited Schedules Fourth Quarter and Full Year 2018 Earnings Conference Call

DENVER, March 26, 2019 (GLOBE NEWSWIRE) — Sundance Energy Australia Limited (ASX: SEA) (NASDAQ: SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas, announced that it will host a conference call to review fourth quarter and full year 2018 results.

Date:   Australia: Thursday 28 March 2019 – United States: Wednesday 27 March 2019

Time:  Australia: 8:00 AM AEDT – United States: 3:00 PM MDT

Australian participants Toll Free dial-in: 1 80 0005 989
Australian (Sydney) Local dial-in: 2 82 239 773

Hong Kong participants Toll Free dial-in: 800 966 253
Hong Kong Local dial-in: 3011 4522

Singapore participants Toll Free dial-in: 800 852 6412
Singapore Local dial-in: 6622 1010

USA Participants Toll Free dial-in:  (844) 831-3022

Webcast Link: http://www.sundanceenergy.net/events.cfm

All participants will be asked for their full name and company when joining the conference call.

For more information, please contact:

United States:
John Roberts
VP Finance & Investor Relations
Tel: +1 (720) 638-2400
 Eric McCrady
CEO and Managing Director
Tel: +1 (303) 543-5703
Australia:
Mike Hannell
Chairman
Tel: + 61 8 8274 2128 or
+ 61 418 834 957

About Sundance Energy Australia Limited

Sundance Energy Australia Limited (“Sundance” or the “Company”) is an Australian-based, independent energy exploration company, with a wholly owned US subsidiary, Sundance Energy Inc., located in Denver, Colorado, USA. The Company is focused on the acquisition and development of large, repeatable oil and natural gas resource plays in North America. Current activities are focused in the Eagle Ford.  A comprehensive overview of the Company can be found on Sundance’s website at www.sundanceenergy.net

Summary Information

The following disclaimer applies to this document and any information contained in it. The information in this release is of general background and does not purport to be complete. It should be read in conjunction with Sundance’s periodic and continuous disclosure announcements lodged with ASX Limited that are available at www.asx.com.au and Sundance’s filings with the Securities and Exchange Commission available at www.sec.gov.  Certain totals or other calculations presented herein may not add precisely due to differences in rounding.

Forward Looking Statements

This release may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same.

These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the discovery and development of oil and natural gas reserves, cash flows and liquidity, business and financial strategy, budget, projections and operating results, oil and natural gas prices, amount, nature and timing of capital expenditures, including future development costs, availability and terms of capital and general economic and business conditions. Given these uncertainties, no one should place undue reliance on any forward looking statements attributable to Sundance, or any of its affiliates or persons acting on its behalf.  Although every effort has been made to ensure this release sets forth a fair and accurate view, we do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Featured in NetworkNewsWire Publication on Soaring Hemp-Based CBD Industry

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) — via NetworkWire — NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF).

To read the full editorial discussing  CBD industry forecasts following the passage of the Farm Bill, visit: http://nnw.fm/Q5q5a

Hemp is making a comeback thanks to the growing popularity of cannabidiol (CBD), an active ingredient found in many forms of cannabis. It’s an ingredient that companies such as Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a creator of plant-based health and wellness products, have been making extensive use of in recent years.

The Farm Bill has been driven in large part by the growing demand for CBD. An obscure and seldom discussed chemical a decade ago, CBD has emerged as an important consumer product. … Identified as a chemical with great potential for health and wellness, CBD has started to be marketed in its own right and is used in products such as the Wildflower Wellness line.

About Wildflower Brands

Wildflower Brands is a company headquartered in Vancouver building reputable brands and quality products that incorporate the synergistic effects of plants and their extracts. For more information, visit the company’s website at www.WildflowerBrands.co

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Receive Instant SMS Alerts from NetworkNewsWire

Text “STOCKS” to 77948

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

Bhang Corporation’s Scott Van Rixel and Jamie Pearson Named to High Times’ Most Influential People in Cannabis

LOS ANGELES, March 26, 2019 (GLOBE NEWSWIRE) — Bhang Corporation (“Bhang” or the “Company”), the global cannabis house of brands with an extensive, award-winning portfolio of products, is proud to announce that Bhang CEO Scott Van Rixel and COO Jamie Pearson have each been recognized by High Times Magazine for their work in the cannabis industry.

Scott Van Rixel has been named to the 2018 High Times’ List of 100 Most Influential People in the Cannabis Industry and Jamie Pearson has been named one of the 2018 High Times Women of Weed, Most Influential Women in Cannabis List.

“We are honored to receive these accolades from High Times” said Scott Van Rixel, CEO of Bhang. “When I started Bhang 9 years ago, I did it with the goal of creating quality and consistent products that consumers love. Today, we are one of the most recognized cannabis brand houses on the planet and I thank all our employees who work tirelessly each day to make this possible.”

“I am proud to lead a passionate, executive team at Bhang that is 90% female” added Jamie Pearson. “Being influential is about listening, elevating others and being willing to take risks for the greater good. Bhang continues to be recognized because we lead by doing what is right before it’s required. It is our company culture.”

Bhang’s long-standing brand, history of operational execution, and innovative product portfolio were built on a strong foundation of quality and consumer safety. With a portfolio of brands comprising over 100 cannabis and CBD based products, Bhang is well positioned to capitalize on the growing consumer appetite for cannabis-derived products.

The High Times 100 celebrates the efforts of the men and women currently shaping the marijuana landscape. The High Times Women of Weed list strives to highlight the women who help shape the evolving cannabis space into an innovative, progressive, and inclusive industry.

Along with their fellow nominees, Scott will be honored at the High Times 100 private gala in Los Angeles on March 27, 2019. Jamie will be honored at the High Times Women of Weed private gala in Los Angeles on March 29, 2019.

About Bhang
Bhang’s award-winning product portfolio of over 100 cannabis and CBD products includes the most-awarded line of cannabis chocolate bars on the planet, as well as a premium collection of pre-rolls, vapes, beverages, gums, mouth sprays and Bhang-branded merchandise. From public companies to platinum recording artists and organic food companies, Bhang has mastered the art of harnessing mutually beneficial partnerships to bring safe, consistent and delicious products to the world. Learn more at gotbhang.com

Contact
Jamie Pearson
COO
j.pearson@bhangcorporation.com
406.208.3488

Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback

  • Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United States
  • Pre-IND feedback from US Food and Drug Administration (FDA) provides clarity to Nanobiotix on US regulatory pathway to approval
  • Clinical trial authorization process to begin in 2H2019 with FDA filing

‘‘We are happy to announce our plan for the registration pathway in Head and Neck cancers in the US. This is a key milestone for the Company and our shareholders, and we look forward to critical next steps toward US development,’’ commented Laurent Levy, Nanobiotix’s CEO.

Paris, France; Cambridge, Massachusetts (USA); March 26, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company has clarity on its regulatory pathway in the treatment of Head and Neck cancers for first-in-class radioenhancer NBTXR3. The announcement follows pre-IND feedback from the US FDA received on March 18, 2019.

Stage III and IV Head and Neck cancers include large primary tumors which may invade underlying structures and/or spread to regional nodes. Treatment of these locally advanced forms of the disease—which makes up more than 50% of all Head and Neck cancers—requires aggressive, concerted measures that often remain a clinical challenge with an estimated 5-year survival rate of 50% with the current standard of care.

Within the Stage III and IV Head and Neck cancers patient population, the Company targets a subpopulation of patients, who have a higher risk of recurrence, or a poorer prognosis as they have an inability to receive cisplatin, the frontline chemotherapy drug for advanced Head and Neck cancers. Additionally, the localization of the tumor focuses on oropharynx, hypopharynx, and oral cavity – representing the majority of Head and Neck cancers.

Based on US FDA feedback, the Company plans to design an Overall Survival (OS)-based, randomized, event-driven Phase II/III clinical trial. 50% of patients will receive standard of care radiotherapy combined with NBTXR3 while the other 50% will receive radiotherapy in combination with cetuximab. The expected total number of patients to participate in this global clinical trial is approximately 600, and an efficacy interim analysis is planned.

Notably, the US FDA has not objected to the use of the data from the dose-escalation phase of the Company’s European Phase I clinical trial in elderly and frail patients with locally advanced Head and Neck cancers as well as the Company’s current CMC (chemical, manufacturing and control) development plan.
The Company plans to initiate its global clinical trial authorization process with US FDA in 2H2019.

About NBTXR3

NBTXR3 is a first-in-class product candidate designed to destroy tumors and metastasis when activated by radiotherapy.

NBTXR3 has a high degree of biocompatibility and requires one single administration before the whole radiotherapy treatment. Nanobiotix believes NBTXR3 has the ability to fit into current worldwide standards of radiation care.

Nanobiotix’s broad clinical program includes 7 clinical trials. In June 2018, Nanobiotix established human proof of concept for this first-in-class product candidate in its Soft Tissue Sarcoma (STS) Phase III clinical trial.

NBTXR3 is actively being studied in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients who are unable to receive chemotherapy or cetuximab and have very limited therapeutic options. Promising results from these clinical studies have been observed from the ongoing Phase I/II trial regarding the local control of tumors.

Nanobiotix is also running an Immuno-Oncology development program. In the United States, Nanobiotix has received approval from the US FDA to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).

The other ongoing NBTXR3 trials are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.

The first market authorization process (CE Marking) is ongoing in Europe in the STS indication.

About NANOBIOTIX: www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contacts

Nanobiotix

Communications Department
+33 (0)1 40 26 07 55
+1 (617) 852-4835
contact@nanobiotix.com

 

Investor Relations Department
+33 (0)1 79 97 29 99
+1 (646) 241-4400
investors@nanobiotix.com

Media Relations  

France – Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr

US – RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 as well as in its 2017 annual financial report filed with the French Financial Markets Authority on March 29, 2018 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.

Attachment